Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo

Shanthi Narla; Sandra Oska; Alexis B Lyons; Henry W Lim; Iltefat H Hamzavi

doi:10.1016/j.jdcr.2020.05.002

Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo

JAAD Case Rep. 2020 May 16;6(7):637-639. doi: 10.1016/j.jdcr.2020.05.002. eCollection 2020 Jul.

Authors

Shanthi Narla¹, Sandra Oska², Alexis B Lyons¹, Henry W Lim¹, Iltefat H Hamzavi¹

Affiliations

¹ Multicultural Dermatology Center, Department of Dermatology, Henry Ford Health System, Detroit, Michigan.
² Oakland University William Beaumont School of Medicine, Auburn Hills, Michigan.

No abstract available

Keywords: CPK, creatinine phosphokinase; FDA, US Food and Drug Administration; JAK, janus kinase; Janus kinase inhibitor; MKTP, melanocyte keratinocyte transplant procedure; creatinine phosphokinase; myalgias; topical ruxolitinib; vitiligo.

Publication types

Case Reports